导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.94% | 3972/4773 |
| 近一周 | -3.20% | 3878/5462 |
| 近一月 | -3.24% | 1640/5421 |
| 近一季 | -2.01% | 1134/5209 |
| 近半年 | -5.39% | 2844/4920 |
| 近一年 | -16.21% | 3766/4366 |
| 近两年 | 28.39% | 2342/2954 |
| 近三年 | 9.26% | 1760/2253 |
| 成立以来 | 55.53% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.53% 4666/4961 |
8.66% 2567/5312 |
- - |
- - |
| 2025 | 3.69% 3101/4813 |
-6.65% 3379/3635 |
4.25% 817/4076 |
10.93% 3224/4524 |
-3.95% 3362/4813 |
| 2024 | 27.62% 183/3463 |
-4.73% 1752/2808 |
-8.19% 2185/3014 |
40.60% 60/3129 |
3.78% 767/3463 |
| 2023 | 4.05% 248/2656 |
4.00% 1074/2280 |
-2.74% 645/2385 |
7.45% 40/2515 |
-4.27% 939/2655 |
| 2022 | -24.65% 1240/2207 |
-17.57% 1220/1919 |
1.89% 1407/2016 |
-15.36% 1273/2113 |
5.99% 400/2208 |
| 2021 | -3.33% 900/1822 |
-14.08% 1166/1255 |
6.54% 738/1330 |
4.07% 383/1466 |
1.48% 915/1822 |
| 2020 | 18.52% 742/1250 |
-9.11% 655/1028 |
8.91% 807/1067 |
18.25% 83/1164 |
1.24% 1040/1184 |
| 2019 | 43.84% 185/1092 |
45.73% 21/739 |
-6.36% 498/788 |
-4.29% 765/850 |
10.13% 160/918 |
| 2018 | - - |
- - |
- - |
0.54% 151/660 |
-1.67% 18/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝券商ETF联接A VS. 长安沪深300非周期A(740101) |